Ceftolozane-tazobactam: When, how and why using it?

• Autores: Inmaculada López Montesinos, Milagro Montero, María Luisa Sorli, Juan Pablo Horcajada Gallego
• Localización: Revista Española de Quimioterapia, ISSN-e 0214-3429, Vol. 34, Nº Extra 1, 2021, págs. 35-37
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • Ceftolozane-tazobactam is currently the most active antipseudomonal agent, including multidrug-resistant extensively drug-resistant strains. Tazobactam provides additional activity against many extended-spectrum beta-lactamases Enterobacterales. Ceftolozane-tazobactam is formally approved for complicated urinary tract infection, complicated intra-abdominal infection, and hospital-acquired and ventilator-associated bacterial pneumonia. The clinical and microbiological success is over 70-80% in many series. However, resistant mutants to ceftolozane-tazobactam have been already described.

    Combination therapies with colistin or meropenem could be among the strategies to avoid the resistance emergence.